Earnings Call Summary | Orthofix Medical(OFIX.US) Q3 2024 Earnings Conference
Earnings Call Summary | Orthofix Medical(OFIX.US) Q3 2024 Earnings Conference
Adjusted The following is a summary of the Orthofix Medical Inc. (OFIX) Q3 2024 Earnings Call Transcript:
以下是Orthofix Medical Inc. (OFIX) 2024年第三季度業績發佈會會議記錄摘要：
Financial Performance:
財務表現：
Q3 2024 reported revenue of $196.6 million, achieving a 7% growth.
Reported a strong free cash flow of $5.9 million achieved ahead of expectations.
Adjusted EBITDA was $19.2 million, realizing margin expansion of approximately $6 million or about 250 basis points year-over-year.
2024年第三季度報告的營業收入爲$19660萬，實現了7%的增長。
報告的自由現金流爲$590萬，超出預期。
調整後的EBITDA爲$1920萬，實現了約$600萬或約250個點子的利潤率擴張。
Business Progress:
業務進展：
Achieved record performances in U.S. sales orthopedics business and in the number of 7D unit placements.
Introduced new finanical targets for 2027, reflecting confidence in sustainable growth.
Expanded U.S. spine fixation by 18% and launched the Reef and WaveForm interbody products.
Growth in BGT business by 9% overall, and 13% in structure due to new market penetration.
在美國銷售的骨科業務和7D設備安裝數量方面取得了創紀錄的業績。
提出了2027年的新財務目標，反映出對可持續增長的信懇智能。
美國脊柱固定業務增長了18%，並推出了Reef和WaveForm椎間體產品。
BGt業務整體增長了9%，結構方面由於新市場滲透增長了13%。
More details: Orthofix Medical IR
更多詳情請見：Orthofix Medical IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容的準確性無法得到完全保證。有關更全面的細節，請參考投資者關係網站。本文僅供投資者參考，不構成任何指導或建議。
